Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + dexamethasone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal, Ophthalmic
01
Overview
Bevacizumab + dexamethasone is a combination therapy consisting of two distinct pharmaceutical agents used primarily in ophthalmology. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby reducing abnormal blood vessel growth and vascular permeability. Dexamethasone is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and anti-edema properties, often delivered as an intravitreal implant for sustained release. The combination has been studied for synergistic effects in treating retinal diseases such as diabetic macular edema (DME) and retinal vein occlusion (RVO), where it can provide both rapid reduction of inflammation/edema and longer-term suppression of VEGF-driven pathology[1][3][7]. This dual approach aims to improve visual acuity, decrease macular thickness, and potentially extend the interval between treatments compared to monotherapy.
- Other names
- bevacizumab + steroid
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + dexamethasone.